Inventor · disambiguated record
Mark W. Rixon
Also filed as: RIXON MARK · RIXON MARK W
43 granted patents·17 pending applications·325 citations·filing 1993–2024
98Inventor score
Files withZYMOGENETICS INC21BRISTOL MYERS SQUIBB CO8LEVIN STEVEN D7ALPINE IMMUNE SCIENCES INC6DOW CHEMICAL CO6
Top patents by PatentIndex Score
60 records- 0197US7501497B2TACI-immunoglobulin fusion proteinsZYMOGENETICS INC·Filed 2005·Granted Mar 10, 2009·32 cites·13 claims
- 0294US7635767B2Compositions comprising polynucleotides encoding TACI-immunoglobulin fusion proteins and methods for producing the sameZYMOGENETICS INC·Filed 2009·Granted Dec 22, 2009·14 cites·46 claims
- 0393US11274140B2APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereofALPINE IMMUNE SCIENCES INC·Filed 2021·Granted Mar 15, 2022·2 cites·30 claims
- 0493US8945553B2Bispecific antibodies to IL-23 and IL-17A/FBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Feb 3, 2015·16 cites·12 claims
- 0592US7842665B2IL-17A and IL-17F antagonistsZYMOGENETICS INC·Filed 2009·Granted Nov 30, 2010·11 cites·6 claims
- 0691US5472693AFamily of anti-carcinoembryonic antigen chimeric antibodiesDOW CHEMICAL CO·Filed 1993·Granted Dec 5, 1995·86 cites·10 claims
- 0790US12304943B2April and BAFF inhibitory immunomodulatory proteins and methods of use thereofALPINE IMMUNE SCIENCES INC·Filed 2024·Granted May 20, 2025·0 cites·5 claims
- 0890US7951919B2TACI-immunoglobulin fusion proteinsZYMOGENETICS INC·Filed 2009·Granted May 31, 2011·7 cites·14 claims
- 0990US7862814B2Method of inhibiting the proliferation of B cell cancers using TACI-immunoglobulin fusion proteinsZYMOGENETICS INC·Filed 2009·Granted Jan 4, 2011·7 cites·18 claims
- 1089US7964711B2Compositions comprising polynucleotides encoding TACI-immunoglobulin fusion proteins and methods for producing the sameZYMOGENETICS INC·Filed 2009·Granted Jun 21, 2011·6 cites·28 claims
- 1188US7622116B2Method of treating inflammation using soluble IL-17RCX4ZYMOGENETICS INC·Filed 2007·Granted Nov 24, 2009·10 cites·15 claims
- 1288US7122632B2Soluble Interleukin-20 receptorZYMOGENETICS INC·Filed 2000·Granted Oct 17, 2006·20 cites·1 claims
- 1386US9346878B2Methods of treating glomerulonephritis associated with IGA nephropathy for TACI-immunoglobulin fusion proteinsZYMOGENETICS INC·Filed 2014·Granted May 24, 2016·4 cites·10 claims
- 1485US2025019413A1April and baff inhibitory immunomodulatory proteins and methods of use thereofALPINE IMMUNE SCIENCES INC·Filed 2024·Application pending·0 cites
- 1585US2025019412A1April and baff inhibitory immunomodulatory proteins and methods of use thereofALPINE IMMUNE SCIENCES INC·Filed 2024·Application pending·0 cites
- 1684US8815238B2Methods for Preparing TACI-immunoglobulin fusion proteinsZYMOGENETICS INC·Filed 2013·Granted Aug 26, 2014·3 cites·12 claims
- 1783US9708401B2IL-17A/F cross-reactive monoclonal antibodies and methods of using the sameBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jul 18, 2017·3 cites·12 claims
- 1881US7883700B2Anti-human IL-21 monoclonal antibodiesZYMOGENETICS INC·Filed 2008·Granted Feb 8, 2011·3 cites·6 claims
- 1981US2024218045A1April and baff inhibitory immunomodulatory proteins and methods of use thereofALPINE IMMUNE SCIENCES INC·Filed 2023·Application pending·0 cites
- 2080US7585948B2Soluble interleukin-20 receptorZYMOGENETICS INC·Filed 2006·Granted Sep 8, 2009·2 cites·9 claims
- 2180US7387780B2Soluble interleukin-20 receptorZYMOGENETICS INC·Filed 2006·Granted Jun 17, 2008·2 cites·7 claims
- 2280US2022185877A1Antibody heavy chain constant domainsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2379US7790676B2Soluble IL-17RA/RC fusion proteinsZYMOGENETICS INC·Filed 2008·Granted Sep 7, 2010·3 cites·25 claims
- 2478US8658766B2Soluble hybrid Fcγ receptors and related methodsBIRKS CARL W·Filed 2009·Granted Feb 25, 2014·4 cites·13 claims
- 2578US8524232B2Methods of treatment using taci-immunoglobulin fusion proteinsRIXON MARK W·Filed 2011·Granted Sep 3, 2013·3 cites·16 claims
- 2676US12202882B2APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereofALPINE IMMUNE SCIENCES INC·Filed 2021·Granted Jan 21, 2025·0 cites·21 claims
- 2776US8093355B2Soluble IL-17RCx4 and fusion proteins thereofKUESTNER ROLF E·Filed 2009·Granted Jan 10, 2012·3 cites·4 claims
- 2876US8084231B2Soluble IL-17RA/RC fusion proteins and related methodsLEVIN STEVEN D·Filed 2010·Granted Dec 27, 2011·3 cites·28 claims
- 2975US9783606B2Polynucleotides encoding IL-17/IL-23 bispecific, IL-17A/F and IL-23p19 antibodiesBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Oct 10, 2017·1 cites·71 claims
- 3075US5993813AFamily of high affinity, modified antibodies for cancer treatmentDOW CHEMICAL CO·Filed 1997·Granted Nov 30, 1999·26 cites·13 claims
- 3174US8124089B2Anti-human IL-21 monoclonal antibodiesJASPERS STEPHEN R·Filed 2009·Granted Feb 28, 2012·1 cites·23 claims
- 3272US11254740B2Methods of treatment using IL-23p19 monoclonal antibodiesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Feb 22, 2022·0 cites·24 claims
- 3372US8361470B2Methods of treatment using anti-human IL-21 monoclonal antibodiesZYMOGENETICS INC·Filed 2012·Granted Jan 29, 2013·1 cites·18 claims
- 3472US8241629B2Anti-human IL-21 monoclonal antibodiesJASPERS STEPHEN R·Filed 2010·Granted Aug 14, 2012·1 cites·11 claims
- 3572US8226948B1Anti-human IL-21 monoclonal antibodiesJASPERS STEPHEN R·Filed 2012·Granted Jul 24, 2012·1 cites·8 claims
- 3672US6641999B1Probing method for identifying antibodies specific for selected antigensDOW CHEMICAL CO·Filed 2000·Granted Nov 4, 2003·2 cites·17 claims
- 3769US2010197575A1Soluble interleukin-20 receptorZYMOGENETICS INC·Filed 2009·Application pending·0 cites
- 3868US6207815B1Family of high affinity, modified antibodies for cancer treatmentDOW CHEMICAL CO·Filed 1995·Granted Mar 27, 2001·15 cites·7 claims
- 3967US10358489B2IL-23p19 monoclonal antibodiesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jul 23, 2019·0 cites·10 claims
- 4066US10358490B2Methods of treating inflammation with IL-17A/F and IL-23P19 bispecific antibodiesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jul 23, 2019·0 cites·18 claims
- 4166US6329175B1Interferon-εZYMOGENETICS INC·Filed 1999·Granted Dec 11, 2001·12 cites·22 claims
- 4265US2020131245A1Treating inflammation with soluble hybrid fcgamma receptorsZYMOGENETICS INC·Filed 2020·Application pending·0 cites
- 4362US9663566B2Soluble hybrid Fcγ receptors and related methodsZYMOGENETICS INC·Filed 2013·Granted May 30, 2017·0 cites·3 claims
- 4462US2017022272A1Il-23 antibodies and methods of using the sameBRISTOL MYERS SQUIBB CO·Filed 2016·Application pending·0 cites
- 4561US10570187B2Soluble hybrid Fcγ receptors and related methodsZYMOGENETICS INC·Filed 2017·Granted Feb 25, 2020·0 cites·9 claims
- 4659US6544505B2Interferon-epsilonZYMOGENETICS INC·Filed 2001·Granted Apr 8, 2003·0 cites·8 claims
- 4758US8242072B2Methods of treating inflammation using soluble IL-17RA/RC fusion proteinsLEVIN STEVEN D·Filed 2011·Granted Aug 14, 2012·0 cites·14 claims
- 4857US2012289684A1Methods of treating inflammation using soluble il-17ra/rc fusion proteinsLEVIN STEVEN D·Filed 2012·Application pending·0 cites
- 4956US2003103986A1TACI-immunoglobulin fusion proteinsFiled 2002·Application pending·0 cites
- 5056US2007280942A1Compositions and methods for modulating immune responsesLEVIN STEVEN D·Filed 2007·Application pending·0 cites
Showing the top 50 of 60 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Mark W. Rixon files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →